Clinical Activity of Combined Telomerase Vaccination and Pembrolizumab in Advanced Melanoma: Results from a Phase I Trial.

导出 OA

翻译打印收藏纠错

作者： Espen B,Ellingsen ^[1] ; Steven,O'Day ^[2] ; Artur,Mezheyeuski ^[3] ; Agnieszka,Gromadka ^[4] ; Trevor,Clancy ^[5] ; Timothy S,Kristedja ^[6] ; Mohammed,Milhem ^[6] ; Yousef,Zakharia ^[4]

作者单位： Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. ^[1] Faculty of Medicine, University of Oslo, Oslo, Norway. ^[2] Ultimovacs ASA, Oslo, Norway. ^[3] Providence Saint John's Cancer Institute, Santa Monica, California. ^[4] HistoOne AB, Uppsala, Sweden. ^[5] NEC OncoImmunity, Oslo, Norway. ^[6] University of Iowa Hospitals and Clinics, Iowa City, Iowa. ^[7] University of Iowa and Holden Comprehensive Cancer Center, Iowa City, Iowa. ^[8]

主题词人类(Humans);黑色素瘤(Melanoma);末端转移酶端粒(Telomerase);接种(Vaccination)

DOI 10.1158/1078-0432.CCR-23-0416

PMID 37378632

发布时间 2023-12-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交